Featured Bioprocessing Editorial
-
New Group Wants 'Phase-Appropriate' Thinking To Retire
9/4/2025
Decisions in cell and gene therapy are not about aligning with arbitrary clinical phases but about balancing risk.
-
When Single-Use Technology Becomes An Economic Imperative
9/3/2025
Industry changes increasingly favor SUT for novel products, even while stainless steel remains an essential part of many process trains.
-
Lilly's Exploring A Universal AAV Purification Method
9/2/2025
Serotype-specific resins don't scale gracefully. One team at Eli Lilly and Company is exploring an alternative that skips affinity resins altogether.
-
CSL Behring's Robotics Push Is One Of The Biggest We've Seen Yet
9/2/2025
An expansion project, including an abundance of automation features, at the CSL's Victoria, Australia, campus earned the company an ISPE Facility of the Year Award.
-
FDA Report Details FY24 Inspections, Shows Big Uptick In Key Countries
8/29/2025
The 2024 Report on the State of Pharmaceutical Quality shows the agency's efforts to normalize post-pandemic oversight under the previous administration.
-
Unpacking Pfizer's Advanced Process Control Platform For Upstream Ops
8/29/2025
Pfizer's advanced process control platform gives modelers more dexterity compared to default controllers, thus speeding up process development.
-
The OBBBA: Biopharmas Unlock R&D Expensing, Global Tax Efficiencies
8/28/2025
Biopharma innovators may soon see major tax breaks thanks to the One Big Beautiful Bill Act (OBBBA). The new legislation introduces targeted tax incentives designed to strengthen domestic R&D and capital investment.
-
New FDA White Paper Ties Quality To Financial Benefits
8/26/2025
The agency presents as a stepwise approach in which companies can make incremental investments rather than committing large amounts of capital upfront.
-
Calculating The Right In-House/Outsource Mix For ADC Manufacturing
8/21/2025
Antibody-drug conjugate innovators often question whether to outsource manufacturing activities or bring them in-house. Here are some key considerations.
-
Report: Nearly 40% Of Biomanufacturers Eyeing Continuous Processing
8/19/2025
Continuous perfusion manufacturing came about before the technology was mature enough to support it. Now, new data suggests an inflection point in the status quo.